pipeline-prospector-insert-v1
X

Find Psychiatry/Psychology Drugs in Phase II Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BTRX-140

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 23, 2020

            Details:

            The Phase 2 proof-of-concept trial is designed to evaluate the efficacy, safety and tolerability of BTRX-140 in approximately 120 patients with major depressive disorder.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ketamine Hydrochloride,Venlafaxine,Sertraline Hydrochloride

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 10, 2020

            Details:

            It showed 60 milligrams of SLS-002 to be safe and well tolerated as a monotherapy or with an oral antidepressant.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NW-3509

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 09, 2020

            Details:

            FDA approved the plan proposed by Newron as well as the protocol for a first, four-week explanatory study in patients with schizophrenia, expected to start enrolling patients in the next few days.